The long-acting muscarinic antagonist (LAMA) tiotropium inhaler (Spiriva Respimat) will be listed on the PBS for children age six and over with severe asthma from 1 March. Federal Minister for Health Greg Hunt announced the listing on 21 February, saying it would extend access from adults to allow up to 30,000 children with asthma. The ...
Already a member?
Enter your email to keep reading.